Royal Society slams UK.gov science shake-up

The UK abolished the Department for Science, Innovation and Technology and transferred science policy to the new Department for Business, Innovation, Science and Trade, while placing AI responsibilities jointly across the Cabinet Office and BIST. Royal Society President Sir Paul Nurse called the move a “quite a big mistake,” warning that embedding science within a business-focused department could constrain cross-sector research and innovation. Science advocates also flagged risks to long-term funding stability, university links and basic research, although ministers said the restructuring is intended to strengthen the government's strategic approach to AI, science and technology.

Analysis

The investable issue is not an immediate earnings shock but a higher policy-risk premium on UK long-duration innovation assets. Fragmented ownership of research, AI, health and higher-education policy raises the probability of delayed grant decisions, less predictable capital allocations and a tilt toward commercially demonstrable projects; that disproportionately pressures university spin-outs and pre-revenue life-science platforms dependent on recurring public and quasi-public funding rounds. IP Group (IPO.L) is the clearest listed transmission vehicle because a weaker domestic funding backdrop can widen private-asset valuation discounts and extend portfolio-company cash burn.

Large-cap pharma should be relatively insulated: AstraZeneca (AZN.L) and GSK (GSK.L) have global R&D footprints and can reallocate programs, while smaller UK discovery companies cannot as easily substitute domestic talent, clinical infrastructure and translational funding. Oxford Instruments (OXIG.L) has some exposure to research-capex cycles, but its global customer mix means a UK policy signal alone is insufficient for a directional short. The near-term market reaction should be negligible absent fiscal detail; the relevant 1-3 month catalyst is a departmental settlement, science-capital budget or university-funding announcement, while the 6-18 month risk is slower spin-out formation and higher financing costs rather than an abrupt reduction in existing research activity.

Consensus may overread the organizational change as inherently anti-innovation. A business-led framework could accelerate procurement, industrial AI deployment and scale-up support if it comes with ring-fenced multi-year budgets; therefore, a broad short of UK technology or biotech is not warranted. The thesis is falsified by a funded cross-department AI/science strategy, real-terms growth in research capital budgets, or explicit multi-year university and translational-research settlements.

Key Decisions for Investors

• No broad UK technology or healthcare beta trade: maintain neutral exposure to AZN.L and GSK.L, whose earnings sensitivity to domestic research-policy execution is low over the next 12 months.
• Set an event-driven watch on IPO.L into the next UK fiscal or departmental funding settlement. Consider a small 3-6 month short only if the announcement freezes real-terms science capital spending, delays grant allocations, or omits university/translational funding; target a 10-15% downside versus a 7% stop, recognizing NAV-discount and short-liquidity risk.
• Avoid initiating a directional short in OXIG.L solely on this development. Reassess only if management identifies UK academic-order weakness or if UK/Europe research-instrument order intake decelerates for two consecutive reporting periods.
• For existing UK venture-biotech exposure, raise required liquidity runway to at least 24 months before adding. Companies requiring a financing within 12 months face the greatest valuation risk if public co-funding and university-linked support become less predictable.